In This Issue
“When Roscius Was an Actor in Rome–” Care for the Elderly with N2-Positive Non–Small-Cell Lung Cancer
Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer
Lung Cancer Detection with Digital Chest Tomosynthesis
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib
Association between Genetic Variants in Pre-MicroRNAs and Survival of Early-Stage NSCLC
High-Risk Human Papillomavirus–Positive Lung Cancer
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in PC9 Cells
Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a–T2bN0M0) Non–Small-Cell Lung Cancer
Interobserver Agreement in the Nuclear Grading of Primary Pulmonary Adenocarcinoma
Variability in the Treatment of Elderly Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer
Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer
Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study
Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients
Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer
Completing the Audit Cycle Improves Surgical Standards in Lung Cancer
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
Polymorphisms in mTORC1 Genes Modulate Risk of Esophageal Squamous Cell Carcinoma in Eastern Chinese Populations
Treatment Modalities for T1N0 Esophageal Cancers
Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
FDG Uptake in the Chest Wall of a Patient with Small-Cell Lung Cancer
Use of Denosumab in a Patient with Non–Small-Cell Lung Cancer and Severe Renal Function Impairment
Benefit of a Second Opinion
Thymic Neuroendocrine Tumor Presenting with the Ectopic ACTH Syndrome
Biostatistics Primer
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age ≥ 70 years) with Stage IIIB/IV Non-Small Cell Lung Cancer